The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A window of opportunity study for preoperative brigatinib in resectable anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC): WILDERNESS trial.
 
Chang Gon Kim
Honoraria - Boryung
Consulting or Advisory Role - Amgen; Johnson & Johnson/Janssen; Novartis; Ono Pharmaceutical; Pfizer
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Dong-A ST; Hanmi; Merck; MSD Oncology; Novartis; Takeda
Research Funding - Ipsen
 
Min Hee Hong
Stock and Other Ownership Interests - GI biome; GI cell
Honoraria - AstraZeneca; BeiGene; Merck; Roche
Consulting or Advisory Role - AstraZeneca; BeiGene; Daiichi Sankyo/Astra Zeneca; Merck; Roche; Yuhan
Research Funding - Yuhan
 
Moonki Hong
No Relationships to Disclose
 
Hyo Sup Shim
No Relationships to Disclose
 
Mina Han
No Relationships to Disclose
 
Eun Yonug Kim
No Relationships to Disclose
 
Chang Young Lee
No Relationships to Disclose
 
Hye Ryun Kim
Honoraria - AstraZeneca; MSD Oncology
Consulting or Advisory Role - AstraZeneca; BeiGene
Speakers' Bureau - ABL Bio; AstraZeneca; MSD Oncology; Ono Pharmaceutical; Roche/Genentech; Yuhan
Research Funding - AstraZeneca (Inst); Yuhan (Inst)